Literature DB >> 16685454

Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells.

Arabel Vollmann1, Hans-Peter Vornlocher, Thomas Stempfl, Gero Brockhoff, Rainer Apfel, Ulrich Bogdahn.   

Abstract

The epidermal growth factor receptor (EGFR, ErbB1) is frequently dysregulated in a variety of solid human tumors, including malignant glioma. EGFR expression has been associated with disease progression, resistance to standard therapies and poor survival. The application of small interfering RNAs (siRNAs) has become an effective and highly specific tool to modulate gene expression, and a wide range of oncogenes have been silenced successfully. Here we show the siRNA-mediated down-regulation of EGFR in two established glioma cell lines with different EGFR expression levels (U373 MG, LN18). The expression of EGFR mRNA and protein was down-regulated by 70-90%. However, siRNA treatment had no inhibitory effect on cell proliferation, migration and activation status of EGFR-coupled signaling cascades. In accordance with these results, gene expression analysis with microarrays revealed only small, albeit specific changes in expression patterns. In conclusion, these data indicate that the specific down-regulation of EGFR might not be sufficient for a single agent therapeutic approach in malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685454

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Swetlana Rot; Jacqueline Kessler; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

2.  Cytomics emerging from cytometry.

Authors:  A Tárnok; G Brockhoff
Journal:  Cell Prolif       Date:  2006-10       Impact factor: 6.831

Review 3.  Using the molecular classification of glioblastoma to inform personalized treatment.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

4.  Current clinical management of patients with glioblastoma.

Authors:  Stephen Lowe; Krishna P Bhat; Adriana Olar
Journal:  Cancer Rep (Hoboken)       Date:  2019-09-04

5.  Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin.

Authors:  Kui Wang; James O Park; Miqin Zhang
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

6.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles.

Authors:  Shyh-Dar Li; Yun-Ching Chen; Michael J Hackett; Leaf Huang
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

7.  Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.

Authors:  Maite Verreault; Sherry A Weppler; Amelia Stegeman; Corinna Warburton; Dita Strutt; Dana Masin; Marcel B Bally
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.